Dual GIPR and GLP‐1R agonist tirzepatide inhibits aeroallergen‐induced allergic airway inflammation in mouse model of obese asthma

This is the authors' abstract. We don't add key points for this paper.

To the Editor,Nearly 1 in 2 adults is projected to be obese by 2030 in the United States. 1 Obesity is a risk factor for asthma and is associated with severe, uncontrolled disease.However, there are no pharmacologic therapeutics specifically designated for obese patients with asthma in the current asthma treatment guidelines from the National Heart, Lung, and Blood Institute of the United States National Institutes of Health.In the past two decades, incretin mimetic drugs such as glucagon like peptide-1 receptor (GLP-1R) agonists have been approved for type 2 diabetes.